PO-1188: Optimal radiotherapy strategy as risk-group in non-metastatic prostate cancer patients (KROG 18-15).

Authors :: Choi, S.H.
Kim, Y.S.
Yu, J.
Nam, T.
Kim, J.
Jang, B.
Kim, J.H.
Kim, Y.
Jung, B.K.
Chang, A.R.
Park, Y.
Lee, S.U.
Cho, K.H.
Kim, H.
Choi, Y.
Kim, Y.J.
Lee, D.S.
Shin, Y.J.
Shim, S.J.
Park, W.
Source :: Radiotherapy & Oncology. 2020 Supplement 1, Vol. 152, pS625-S625. 1p.
Publication Year :: 2020
Abstract: Poster: Clinical track: Prostate PO-1188: Optimal radiotherapy strategy as risk-group in non-metastatic prostate cancer patients (KROG 18-15) S.H. Choi, Y.S. Kim, J. Yu, T. Nam, J. Kim, B. Jang, J.H. Kim, Y. Kim, B.K. Jung, A.R. Chang, Y. Park, S.U. Lee, K.H. Cho, J.H. Kim, H. Kim, Y. Choi, Y.J. Kim, D.S. Lee, Y.J. Shin, S.J. Shim, W. Park, J. Cho. [Extracted from the article]

Full Text Access

Tools